CHICAGO, Ill., July 23, 2026
SimBioSys®, an AI-driven precision medicine company, has announced a strategic partnership with Ferrum Health to expand access to its FDA-cleared TumorSight® Viz platform through Ferrum’s Model Hub, enabling healthcare organizations to integrate AI-powered breast cancer surgical planning into routine clinical workflows. The collaboration combines SimBioSys’ advanced surgical planning technology with Ferrum’s enterprise-grade AI governance and deployment platform, allowing hospitals and health systems to implement, monitor, and scale artificial intelligence solutions more efficiently. The partnership is designed to improve clinical decision-making by providing surgeons with patient-specific three-dimensional visualizations derived from standard breast MRI scans, supporting greater precision in surgical planning while maintaining trusted governance, workflow integration, and enterprise-wide performance monitoring. As healthcare providers continue to accelerate the adoption of clinical AI, the collaboration represents another important step toward expanding access to validated, scalable, and interoperable technologies that enhance personalized cancer care.
FDA-Cleared TumorSight Viz Enhances Breast Cancer Surgical Planning
At the center of the partnership is TumorSight® Viz, an FDA-cleared AI-powered surgical planning platform that converts routine breast magnetic resonance imaging (MRI) into detailed interactive 3D anatomical visualizations. The platform enables surgeons to gain deeper insight into each patient’s unique tumor anatomy, supporting more personalized treatment planning and improved surgical confidence. By integrating TumorSight Viz within Ferrum Health’s Model Hub, healthcare organizations can deploy the platform directly into existing clinical infrastructure without requiring extensive workflow redesign. The collaboration simplifies implementation while allowing clinicians to access AI-generated insights within familiar care environments. The solution is intended to support more informed surgical decision-making through reproducible, anatomy-specific visual intelligence that enhances precision during breast cancer treatment planning. The availability of TumorSight Viz through a centralized AI deployment platform also enables broader adoption across hospitals, cancer centers, and integrated healthcare systems.
Enterprise AI Platform Strengthens Clinical Integration
The partnership extends beyond software availability by combining clinical artificial intelligence with enterprise-level AI governance, monitoring, and deployment capabilities. Ferrum Health’s Model Hub provides health systems with centralized oversight for multiple AI applications, enabling organizations to validate model performance, monitor clinical effectiveness, and manage AI solutions across numerous departments from a single platform. Adding TumorSight Viz expands Ferrum’s growing portfolio of clinically validated AI technologies supporting medical imaging, diagnostics, and patient care delivery. Through this integration, hospitals can deploy advanced surgical planning capabilities while maintaining performance transparency, operational consistency, and secure implementation. The collaboration addresses one of healthcare’s most significant AI adoption challenges by simplifying deployment and enabling healthcare providers to scale validated technologies across enterprise environments without disrupting existing clinical operations.
Advertisement
Partnership Accelerates Precision Medicine Adoption
The collaboration reflects the increasing role of artificial intelligence in precision oncology, where advanced imaging analytics and individualized visualization tools are transforming cancer diagnosis and treatment planning. TumorSight Viz is already being utilized by leading clinical and research institutions, demonstrating reproducible performance in generating patient-specific anatomical insights for breast cancer surgery. By leveraging Ferrum’s scalable AI infrastructure, SimBioSys aims to expand access to its innovative technology across a broader network of healthcare organizations, helping surgeons make more informed clinical decisions while supporting personalized treatment strategies. As hospitals continue investing in enterprise AI ecosystems that integrate imaging, diagnostics, and clinical workflows, the partnership positions both companies to accelerate the adoption of intelligent surgical planning solutions that improve workflow efficiency, clinical confidence, and patient-centered cancer care through advanced AI-powered precision medicine.
Source: SimBioSys, Ferrum Health press release
